UBS Group reaffirmed their buy rating on shares of RECKITT BENCKIS/S (OTCMKTS:RBGLY) in a research report report published on Wednesday morning, The Fly reports.
RBGLY has been the topic of a number of other research reports. Zacks Investment Research upgraded shares of RECKITT BENCKIS/S from a hold rating to a buy rating and set a $18.00 target price on the stock in a research report on Thursday, May 7th. JPMorgan Chase & Co. reiterated an overweight rating on shares of RECKITT BENCKIS/S in a research note on Friday, June 26th. Royal Bank of Canada restated an underperform rating on shares of RECKITT BENCKIS/S in a research note on Wednesday. Morgan Stanley reiterated an overweight rating on shares of RECKITT BENCKIS/S in a research report on Monday, June 15th. Finally, Berenberg Bank restated a buy rating on shares of RECKITT BENCKIS/S in a research report on Friday, July 10th. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and six have assigned a buy rating to the stock. RECKITT BENCKIS/S presently has a consensus rating of Buy and an average price target of $18.00.
RBGLY stock opened at $20.41 on Wednesday. RECKITT BENCKIS/S has a 52 week low of $12.76 and a 52 week high of $21.00. The company has a market capitalization of $72.40 billion, a PE ratio of 22.68 and a beta of 0.71. The company’s 50-day simple moving average is $18.94 and its 200 day simple moving average is $16.93. The company has a debt-to-equity ratio of 0.91, a quick ratio of 0.42 and a current ratio of 0.56.
Reckitt Benckiser Group plc manufactures, markets, and sells health, hygiene, and home products. The company offers products for the treatment of analgesic and gastro-intestinal problems, sore throat, cough, pain, and flu, as well as wellness products in sexual wellbeing, footcare, vitamins, and supplements under the Durex, Gaviscon, Nurofen, Mucinex, Scholl/Amopé, and Strepsils brand names.
Featured Story: What is a capital gain?
Receive News & Ratings for RECKITT BENCKIS/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RECKITT BENCKIS/S and related companies with MarketBeat.com's FREE daily email newsletter.